QGel was a biomedical technology company specialized in organoid applications and solutions. QGel technology was acquired by a Precision Cancer Technologies Inc. (PCT) in 2021.
The company raised CHF 25 million to develop the QGel technology consisting of a portfolio of 5 international patent families.
QGel's hydrogel technology mimics the microenvironment surrounding cells inside the human body. This feature facilitates growing patient cells from biopsies in a lab without losing the unique biological characteristics of the patient.
With patient samples grown in a lab, many potential anti-cancer therapies can be tested on patient cancer avatars, ex vivo, to observe how each tumor clone responds to each therapy option, giving oncologists insight to expected patient response.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Lausanne, Vaud 1015, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.pct.bio
- Keywords
- New Orleans.
- HQ
- Lausanne, Vaud
Qgel Sa Questions
Qgel Sa's website is https://www.pct.bio
Qgel Sa's LinkedIn profile is https://ch.linkedin.com/company/qgel
Qgel Sa has
2 employees.
View email and phone details for 2
employees at Qgel Sa.
Qgel Sa's industry is
Biotechnology Research
Qgel Sa's top competitors are
Tigen,
Ems - Electro Medical Systems,
Eden Tech,
Axosim Technologies,
Grip Molecular Technologies, Inc,
Philips,
Lifenet Health,
Insphero,
Tissuelabs,
Abionic.
Qgel Sa's categories are Biotechnology Research
Qgel Sa's founding year is 2009
